- Metaplastic breast cancer
|
-
Any history of leptomeningeal disease or carcinomatous meningitis
|
-
Any prior systemic therapy for metastatic breast cancer
|
-
Prior treatment with fulvestrant or any selective estrogen-receptor degrader
|
-
Prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway
|
-
Type 2 diabetes requiring ongoing systemic treatment at the time of study entry, or any history of Type 1 diabetes
|
-
Known and untreated, or active CNS metastases. Patients with a history of treated CNS metastases are eligible
|
-
Active inflammatory or infectious conditions in either eye, or any eye conditions expected to require surgery during the study treatment period
|
-
Please contact study team for more eligibility criteria
|